Addition of Clarithromycin in Multiple Myeloma Patients as impact of outcome and management

Abstract

There is evidence that clarithromycin is a potent and continuous inhibitor of autophagy in both myeloma and chronic myeloid leukaemia cells.

The combination of clarithromycin and bortezomib resulted in increased cytotoxicity compared to bortezomib alone .

The aim of the study is to determine the benefits and risk of adding clarithromycin as standard regimen in multiple myeloma patients whether denovo or refractory pre bone marrow transplantation and its effect on remission rates in these patients. This was a douple arm intervention study performed at Hematology Bone marrow transplantation ward and Hematology outpatient clinic at Ain shams University Hospital . A total of 97 patients were enrolled in this study , 30 of them are act as a control and receiving standard chemotherapy only ,and 30 patients received VCD in addition to clarithromycin and 37patients received VRD in addion to clarithromycin . All of patients under study do not underwent bone marrow transplantation.